Valuation dashboard for ADC Therapeutics S.A. (ADCT) with P/E N/A, P/B -0.56, EV/EBITDA -3.82 and dividend yield 0.00%. DCF, Graham Number and Earnings Power Value models plus sector comparison against other Healthcare companies.
ADC Therapeutics S.A. operates as a commercial-stage biotechnology company, focused on developing antibody-drug conjugates (ADCs) for the treatment of hematological malignancies and solid tumors. Its flagship product, ZYNLONTA, is presently being evaluated in multiple clinical trials: a Phase II study for relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma; a Phase III trial assessing its combination with rituximab for second-line, transplant-...
Analysis Summary
Trailing-twelve-month margins: gross margin 88.7%, operating margin -125.8%, net margin -123.0%.
At the current price of $1.05, ADCT has negative trailing earnings (P/E not meaningful) and an ROE of 44.63%. Market capitalisation stands at $134M.
Balance sheet quality for ADCT: current ratio of 4.4. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| Price / Book | -0.56 |
| EV / EBITDA | -3.82 |
| Dividend Yield | 0.00% |
Valuation Models
| DCF Fair Value | $-10.83 |
| vs Current Price | -1131.1% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| ADCT | ADC Therapeutics S.A. | $134M | 44.6% | ||
| 0QZU.L | Vertex Pharmaceuticals Incorporated | $131.8B | |||
| VRTX | Vertex Pharmaceuticals Incorporated | $130.3B | 29.68 | 6.45 | 23.3% |
| 0R2M.L | Regeneron Pharmaceuticals, Inc. | $84.0B | |||
| REGN | Regeneron Pharmaceuticals, Inc. | $79.8B | 18.79 | 2.57 | 13.8% |
| ARGX | argenx SE | $61.2B | 36.30 | 7.40 | 21.7% |
| MRNA | Moderna, Inc. | $57.8B | 1.34 | -39.2% | |
| RVMD | Revolution Medicines, Inc. | $41.7B | 15.96 | -96.4% |
Price
| Price | $1.05 |
| Market Cap | $134M |
| Exchange | NYSE |
| Country | CH |
Profitability
| Return on Equity | 44.63% |
| Return on Invested Capital | -49.54% |
| Return on Assets | -34.69% |
| Gross Margin | 88.75% |
| Operating Margin | -125.83% |
| Net Margin | -123.03% |
Related companies: ALMS · AUTL · BCYC · FDMT · LCTX · LXRX · NMRA
Explore sector: Healthcare · Biotechnology
More sections of ADCT: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks